- Home
- LIVN
LIVN
LivaNova PLC
as 06-20-2025 4:00pm EST
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
| Founded: | 1987 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 2.1B | IPO Year: | 1993 |
| Target Price: | $59.29 | AVG Volume (30 days): | 601.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $32.48 - $57.35 | Next Earning Date: | 07-30-2025 |
| Revenue: | $1,275,380,000 | Revenue Growth: | 7.62% |
| Revenue Growth (this year): | 8.1% | Revenue Growth (next year): | 5.76% |
Latest LivaNova PLC News
LIVN Breaking Stock News: Dive into LIVN Ticker-Specific Updates for Smart Investing
Morningstar Research
11 days ago
Analyst Report: LivaNova PLC
Medical Device Network
15 days ago
LivaNova completes epilepsy treatment study of VNS Therapy
Business Wire
16 days ago
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
Business Wire
16 days ago
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy
MT Newswires
17 days ago
LivaNova Seeks Reconsideration of National Medicare Coverage for VNS Depression Treatment
Business Wire
17 days ago
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression
Argus Research
a month ago
LIVN: Raising target price to $47.00
MT Newswires
a month ago
Wolfe Upgrades LivaNova to Outperform From Peer Perform, Price Target is $60
Compare LIVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LIVN LivaNova PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.